Vomorolone is not currently approved for use in treatment of PMR. I'm just posting this so everyone is aware of its existence. There are also currently no clinical trials for its use with PMR, but here is what preplexityai.com says:
Vamorolone was not approved for the treatment of DMD (Duchenne muscular dystrophy) in UK in January this year. They said “Vamorolone is an effective treatment for DMD, but its relative effectiveness compared with other corticosteroids was highly uncertain… [and] there was not enough evidence to conclude that vamorolone is a cost-effective treatment option.” It looks like it will not be approved for PMR in the near future.
The 2022 studies linked below suggest vamorolone (Agamree) is not superior to prednisolone, but it is a bit different. For example, it is usually swallowed in a tiny amount of liquid, and it penetrates the brain much more readily (which is not necessarily a good thing). "Bone turnover markers declined with prednisone but not with vamorolone. Boys with DMD at baseline showed low ACTH-stimulated cortisol and high incidence of adrenal insufficiency. All 3 treatment groups led to increased adrenal insufficiency."
Vamorolone has its own extensive list of potential side effects, just like all corticosteroids. They include the development of cushingoid features, psychiatric disorders, vomiting, weight gain, vitamin D deficiency, and cough.
The normal dosing regime for patients with DMD (Duchenne muscular dystrophy) is 0.75 mg/kg/dy of prednisolone, but 2 to 6 mg/kg/dy of vamorolone, which suggests the new drug is much less potent.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.